Lisa is a stock analyst with nearly 25 years of investment research experience. She earned a MBA in Finance from the University of Chicago in 1987 and began her career in investment research that same year as part of the equity research team at Kemper Financial Services. In 1989, Lisa joined the Financial Relations Board, a large investor relations consulting firm, rising to the position of director of financial analysis.
During her tenure with FRB, Lisa was a consultant to Boston Market, MGI Pharma, Devon Energy and other Fortune 1000 companies. In 2000, Lisa left to become director of investor Relations for a NYSE-listed REIT, serving in that position until the REIT was acquired. Since then, Lisa has worked as a stock analyst for independent research firms, investment newsletters and financial websites.
Analyst Articles
The best investment advice I ever received is to look for “megatrends” — trends that fundamentally change how we live. These trends often last decades and are usually the result of changing demographics or new technologies. Megatrends frequently present ground-floor opportunities for investors. Recognizing and investing in companies that benefit… Read More
Every year, Goldman Sachs hosts the “Communacopia Conference,” an investor gathering that focuses on various public companies involved in mass media and advertising. The conference, which is now in its 20th edition, is a real chance for firms to hobnob and glad-hand, but amid all the buzz at this year’s… Read More
Financial media firm Forbes just came out with the Forbes 400, which ranks the 400 richest Americans. Bill Gates topped the list with an estimated net worth of $59 billion. This impressive amount of wealth also qualified him for second in the world, behind… Read More
A weak stock market sure can make short sellers look wise. So I’ll give a bit of credit to the broader market for my mostly successful set of recent short predictions. Back in May, I highlighted five stocks that looked… Read More
If you haven’t been following the deteriorating debt situation in Europe, then these headlines pretty much say it all. “Stocks Slide as European Crisis Grows” “Euro Debt Fears Pummel Wall Street” “Greece Default Risk Jumps to 98%” #-ad_banner-#How can a small… Read More
We’re more than a decade removed from the dot-com crash, and many investors still recall those days with dread, when the market plunged almost daily, seemingly without end. That same mood pervades Wall Street today, and the fear is once again palpable. But… Read More
Despite a decade’s worth of turbulence for the market, much of it painful, it’s amazing how so many investors keep coming back to the same stocks and the same stories that have already punished their portfolios at least once. Examples of these let-downs include… Read More
For the millions of Americans who suffer from high cholesterol, Nov. 30 will be a big day. That’s when Pfizer’s (NYSE: PFE) blockbuster drug Lipitor will lose patent protection, promising massive savings for high-cholesterol patients. The $7 billion drug (according to projected 2011 sales) also represents a big deal for… Read More
You hear it all the time. Save for retirement! Many financial experts — including my favorite, Suze Orman — tell you to contribute to a Roth IRA or traditional IRA outside of your… Read More
In just a matter of days, the third quarter will finally come to an end, and barring an end-of-the month rally, investors will be tallying up the losses. As it currently stands, the S&P 500 is on track for a 15% loss, erasing all of the gains of the previous… Read More
